Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Notification  of managers' and closely related parties' transactions with Dampskibsselskabet NORDEN A/S' shares in connection with share buy-back program

ANNOUNCEMENT NO. 201 - 20 NOVEMBER 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 186/23 and 187/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Dampskibsselskabet NORDEN A/S – weekly report on share buy-back

ANNOUNCEMENT NO. 200 - 20 NOVEMBER 2023   On 2 November 2023, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 2 November 2023 up to and including no later than 31 January 2024. For details, please see announcement no. 186 of 2 November 2023.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 30 million (approximately DKK 210

Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor

Cyxone (publ), a biotech company in autoimmune diseases, re-engages Professor Rikard Holmdahl as Scientific Advisor for the company’s projects in autoimmune diseases.Rikard Holmdahl has long established experience and expert knowledge in immunology and autoimmune diseases. Professor Holmdahl is one of Sweden’s leading scientists in immunology who has contributed to very valuable insights into the mechanisms causing chronic inflammatory diseases such as multiple sclerosis and rheumatoid arthritis. He has during his career been acknowledged with several prestigious scientific prizes for his

Company Announcement No. 105, 2023 – Debtor composition in Nordea Kredit (CK 92)

Monthly information on debtor composition in Nordea Kredit published in order to comply with the Transparency Directive's disclosure requirements.Nordea Kredit hereby publishes monthly data on debtor composition of all callable bond series. The information is subject to disclosure requirements in the Securities Trading Act § 27a section 1.The information is also published in the usual way via the Copenhagen Stock Exchange / OMX.   Nordea Kredit Realkreditaktieselskab   Klaus Johnbeck Phone : +45 55 47 05 11

AddSecure named Career Company 2024

"AddSecure is the obvious choice for those who want to shape their career in an international and dynamic environment. With a strong focus on secure IoT and tech solutions, the company has created a workplace where competence and commitment are central". This is the jury’s motivation for appointing AddSecure a Career Company 2024.Every year, the organization “Karriärföretagen” (Career Companies) highlights employers who offer unique career and development opportunities with a focus on newly graduated students and young talents. The purpose is to make it easier for young professionals, but

Read original

P CAPITAL ANNOUNCES NAV OF P CAPITAL PARTNERS IV

Press releaseStockholm, 20 November 2023 Since P Capital Partners IV AB decreased its contributed capital by EUR 13.4 million through a repayment to debenture holders and owners, the Net Asset Value of the P Capital Partners IV AB participation loan has been calculated. The Net Asset Value is to be calculated at the close of each quarter and in conjunction with a capital increase or decrease. The repayment amounted to EUR 4.00 per Series A participation loan debenture and EUR 0.049 million to the owners. At the close of business on 17 November 2023, the Net Asset Value of the P

Konecranes to upgrade reactor hall overhead crane at Sweden’s Oskarshamn Nuclear Power Plant

Konecranes has won a contract to upgrade to the reactor hall overhead crane at the Oskarshamn Nuclear Power Plant in Sweden. The crane plays a crucial role in servicing the reactor and managing the removal of spent fuel casks, complying with stringent regulatory standards. The order was booked in Q4 2023. The upgrade of the legacy Konecranes crane not only ensures safety compliance but also meets the evolving regulatory requirements in the nuclear industry. The contract has a two-year timeline, during which Konecranes will undertake engineering, manufacturing, delivery and installation

Kim Pedersen appointed new Deputy CEO of PostNord, CEO of PostNord Denmark and Head of PostNord International

Kim Pedersen has been appointed Deputy CEO of PostNord, CEO of PostNord Denmark and Head of PostNord International. Most recently, he was leading the global sales and marketing at A.P. Moller – Maersk. Kim will take up his new duties on December 1, 2023.Kim Pedersen brings many years of experience within the international transport and logistics sector, with a proven track record of sustainable profitable growth. Kim has held senior executive positions as CEO and CCO for global transport companies such as Geodis and comes lately from a Senior Vice President role at Maersk leading the global

RLS Global ansöker om konkurs

Styrelsen i RLS Global AB (publ) (”RLS” eller ”Bolaget”) har idag beslutat att ansöka om att försätta Bolaget i konkurs. Konkursansökan kommer att lämnas in idag den 20 november 2023 till Göteborgs Tingsrätt.Orsaken till konkursansökan är att RLS, trots intensivt arbete under 2023, inte har hittat en sund och fungerande lösning på sin ansträngda finansiella situation, på kort och medellång sikt. Styrelsen och ledningen har även under en längre tid arbetat hårt med målsättningen att utvidga de strategiska partnerskap som Bolaget behöver. Detta arbete har dessvärre under rådande

BioStock: Lipum’s SOL-116 sparked interest at BIO-Europe

On November 6-8, it was once again time for BIO-Europe, Europe’s largest partnering conference in the life science sector. Lipum’s CEO Einar Pontén and business developer Sven Undeland were there to present the latest progress in the company’s drug development to potential partners and investors. Einar Pontén shared his insights from this year’s BIO-Europe in Munich.Read the full article at biostock.se: https://www.biostock.se/en/2023/11/lipums-sol-116-sparked-interest-at-bio-europe/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Repurchase of Truecaller B shares in week 46, 2023

During 6 November 2023 and 10 November 2023 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 1,035,000 own B shares (ISIN: SE0016787071) as part of the share buyback programme initiated by the board of directors.The share buybacks form part of the share buyback programme announced by Truecaller on 7 June 2023. The share buyback programme will run between 7 June up until the 2024 AGM which will be held in May 2024, and is carried out in accordance “Emittentregelverket”. On the Annual General Meeting 2023 the Board was authorized to buy back B-shares up until

Buybacks of shares in ITAB during week 46 2023

During the period between 13 and 17 November 2023, ITAB Shop Concept AB (publ) (”ITAB”) (LEI-code: 2138001H6FCSZBP26351) has repurchased in total 26,749 own ordinary shares (ISIN: SE0015962097) as part of the share buyback program initiated by the Board of Directors in order to optimise the capital structure.The share buybacks form part of the share buyback program in a maximum amount of MSEK 50 that ITAB announced on 28 September 2023. The share buyback program, which runs from 29 September 2023 until 14 May 2024, is being carried out in accordance with the EU Market Abuse Regulation (“MAR”

Lecanemab winner in two categories at The Scrip Awards 2023

Stockholm, November 20, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.The Scrip Awards celebrate the best innovations and achievements of the international biopharma industry. The award for Best New Drug recognizes excellence in pharmaceutical development and celebrates lecanemab as the first and only treatment approved in Japan and the United States shown to reduce the rate of disease progression and to slow cognitive

BioStock: Arcede proceeds to stability study in collaboration with Iconovo

Lund-based Arcede Pharma continues to advance its project with RCD405. The company recently concluded the toxicology program and can now announce that the collaboration on the formulation work with Iconovo is progressing with good results. The formulation work has been completed and the next step will be to conduct a technical stability study and then take the drug candidate into the clinic.Read the full article at biostock.se : https://www.biostock.se/en/2023/11/arcede-proceeds-to-stability-study-in-collaboration-with-iconovo/ This is a press release from

Metso delivers technology to copper electrorefinery in USA

Metso Corporation’s press release on November 20, 2023, at 09:00 a.m. EETFreeport-McMoRan has awarded Metso an order for the delivery of a state-of-the art tankhouse material handling solution to their El Paso electrorefinery in Texas, USA. The order value exceeding EUR 10 million is booked in Minerals segment’s 2023 fourth-quarter orders received. Metso’s scope of delivery includes Outotec Anode Preparation and Cathode Stripping Machines, both based on proven design ensuring high safety and long-term reliability. Both machines utilize modern robotic electrode handling to optimize layout

Peab renovates hotel in Vantaa

Peab has been commissioned to renovate a hotel in Vantaa on the outskirts of Helsinki. The customer is Kiinteistö OY Haukipurontie (Keva) and the contract is worth EUR 13 million.The property Peab will renovate is a hotel building with seven floors and 271 rooms in all. The hotel was built in 1991 and extended in 2003. The project comprises renovating the premises and updating technical installations. The hotel’s main lobby will be modernized by opening up the space. The load-bearing construction of the hotel’s basement garage will also be refurbished. “We really look forward to working

Portfolio Update

20 November 2023   Menhaden Resource Efficiency PLC (the “Company”) LEI: 2138004NTCUZTHFWXS17     Portfolio Update     Following the completion of KKR's sale of its remaining 50% stake in X-Elio, the Company received a final distribution of USD 16.9 million. The investment delivered an aggregate return on invested capital of 2.15x in USD and 2.6x in GBP to the Company, and demonstrates the value of the Company’s ability to partner with leading global private equity firms.     The Company is actively evaluating new private equity opportunities. In the

Veidekke: Exercise of employee share options in Veidekke ASA

A total of 6 participants in the Company's share option program have on November 17[th] 2023 exercised a total of 2 200 options at a strike price of NOK 43.05.A total of 34 participants the Company's share option program have on November 17[th ]2023 exercised a total of 25 840 options at a strike price of NOK 47.36. Following the exercise, the employees will purchase 28 040 shares. These shares will be transferred during December 2023. Shares acquired through the program have a sales restriction on one year after exercise date. For further information, please contact: Jørgen Wiese

Cloudberry Clean Energy ASA | Transactions made under the share buy-back programme

Oslo, 20 November. On October 31 Cloudberry Clean Energy ASA (“Cloudberry”) announced its decision to initiate a share buy-back programme· The duration of the buy-back programme:  31 October 2023 until 31 December 2023 at the latest. · Size of the buy-back programme: Up to 3,000,000 shares, with a maximum total consideration of NOK 43,800,000. · During week 46 2023, Cloudberry purchased 304,200 own shares at an average price of NOK 10.0626 per share. Below is an overview of the transactions carried out under the buy-back programme. Date                           | Number of

New Group structure for future growth

To strengthen the platform for the next growth phase, Indutrade changes the Group structure to five international Business Areas with clear strategic focus on different business sectors and technologies. The purpose of the change is to enhance both the organic and acquisition growth agendas, by further encouraging knowledge sharing between companies within similar market sectors and segments.“This year, Indutrade has provided sustainable, profitable growth for 45 years. Our value-based culture, with a long-term focus on the people, entrepreneurship and decentralisation has been the key to

Fiven ASA announces investor meetings to evaluate an up to EUR 110m senior secured sustainability-linked floating rate bond issue and provides a financial update

Fiven ASA (the "Company") has mandated Pareto Securities AB to arrange a series of investor meetings commencing on 21 November 2023. Subject to, inter alia, market conditions, a 3-year senior secured sustainability-linked floating rate bond issue in an initial amount of up to EUR 110 million (the "Bond Issue") within a framework of up to EUR 170,000,000 may follow.   The proceeds from the contemplated Bond Issue will be used to inter alia finance the repayment of the Company's existing outstanding EUR 70,000,000 senior secured sustainability-linked bonds with ISIN SE0016075196,

Sobi to present new data at ASH 2023 Annual Meeting

Sobi® will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of December 2023. During the meeting several analyses will be presented in patients with haemophilia A, paroxysmal nocturnal hemoglobinuria (PNH), immune thrombocytopenia (ITP), relapsed or refractory diffuse large b-cell lymphoma, myelofibrosis, and haemophagocytic lymphohistiocytosis.   “We take pride in our expanded commitment to individuals affected by rare diseases, which we are pleased to highlight at this year's ASH meeting, with research that

Duni Group's science-based targets approved

Duni Group's science-based targets have been approved by the Science Based Target initiative. Setting science-based targets ensures the work towards further reductions of greenhouse gas emissions in line with the Paris Agreement. This is an important step towards the goal of reaching net-zero across the value chain by 2050.    Using science-based targets is a comprehensive and transparent way for Duni Group to show the long-term work to further reduce greenhouse gases. The performance will be followed-up and communicated externally annually.   Important milestone   "This

There are no items matching the current filter
There are no more items matching the current filter
Back to top